ut-logo website  
 
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

You are here: Home Conferences Conferences DGU 2011 Session Highlights
Renal Cancer Highlights

Renal Cancer Highlights

DGU 2011 - Impact of kidney function on the accuracy of urine-based tests for the diagnosis of urothelial cancer of the bladder - Session Highlights

  • Print
HAMBURG, GERMANY (UroToday.com) - The authors investigated 449 consecutive patients with hematuria but without a history for urothelial cancer of the bladder.

Read more...

DGU 2011 - Histologic subtypes of renal cell carcinoma demonstrate different activation of the mTOR pathway - Session Highlights

  • Print
HAMBURG, GERMANY (UroToday.com) - With a tissue microarray, the expression of mTOR, phosphorylated mTOR (p-mTOR), and 4E binding protein in different tumor tissue samples were analyzed.

Read more...

DGU 2011 - Treatment of patients with metastatic renal cell carcinoma: Reality in Germany - Session Highlights

  • Print
HAMBURG, GERMANY (UroToday.com) - In a clinical database on patients with advanced or metastatic renal cell carcinoma (RCC), the first 622/1000 planned patients from > 100 centers were analyzed.

Read more...

DGU 2011 - Intrinsic resistance to treatment with tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma - Session Highlights

  • Print
HAMBURG, GERMANY (UroToday.com) - The authors looked at 35 patients with metastatic renal cell carcinoma showing primary resistance to the first tyrosine kinase inhibitor (TKI, 28 patients receiving sunitinib and 5 patients receiving sorafenib).

Read more...

DGU 2011 - Nephron-sparing surgery in patients with renal tumors >7 cm: Functional and oncological outcome - Session Highlights

  • Print

HAMBURG, GERMANY (UroToday.com) - The authors from two German academic centers analyzed their database with regard to elective nephron-sparing surgery for tumors > 7 cm.

Read more...

DGU 2011 - Sorafenib (SOR) dosage patterns in > 4600 patients with renal cell carcinoma, including the elderly and patients treated for > 12 months: Results from an integrated database of 8 company-sponsored trials - Session Highlights

  • Print
HAMBURG, GERMANY (UroToday.com) - The authors investigated 4,684 patients from 6 clinical trials and 2 expanded-access trials and analyzed the median dosage of sorafenib in all patients, elderly patients and patients having received sorafenib for > 12 months.

Read more...